TrueLab TrueLab Care
Evidence reviews · DOI-cited sources · research use only
Guide 28 Oct 2026 · 3 min read · 2 sources

Aliquot first: the five minutes that protect a stock

Splitting a solution into single-use portions is the most consistently recommended and most consistently skipped step in peptide handling. The advice is not fussiness, it exists because each freeze, thaw cycle does damage by a specific mechanism, and the damage does not undo itself.

TL

TrueLab Research Team

Reviewed 28 Oct 2026 · Summarises peer-reviewed literature · Not medical advice

Key takeaways

  • Freezing concentrates everything dissolved into a shrinking liquid fraction at the ice interface, a high-concentration, pH-shifted micro-environment.
  • That environment is where association begins, and association into aggregates is largely irreversible[^1].
  • Damage is per cycle, so the count matters more than total time frozen: one vial thawed six times sees six of these events.
  • Aliquoting converts an unknown number of cycles into exactly one, at the cost of a few minutes and some tubes.
  • The same reasoning explains why a stock should be made at the volume you will use, not the volume that empties the vial.

"Aliquot before freezing" appears in every handling note ever written for peptides and proteins, which is roughly why nobody reads it. It sounds like the kind of advice that exists to be thorough.

It exists because freezing does something specific and destructive, and because doing it repeatedly to the same solution multiplies the effect.

Freezing is not simply "getting cold"

The intuition is that low temperature slows chemistry, so freezing should preserve things. That much is true, but it describes only what happens after the solution is frozen, and skips the transition, which is where the damage occurs.

What actually happens as a solution freezes

The damage is done at the boundary, not by the cold itself

Ice crystals begin to form

Pure water crystallises first

Solutes are excluded from the crystal

Peptide, salts and buffer components are pushed into the remaining liquid

The liquid fraction shrinks and concentrates

Concentration rises sharply; buffer components can crystallise unevenly and shift the pH

Molecules associate at the interface

High concentration plus altered pH is the condition aggregation needs[1]

As ice forms, it forms as fairly pure water. Everything dissolved, the peptide, salts, buffer components, is excluded from the growing crystal and pushed into the liquid that remains. That liquid fraction shrinks continuously, so the concentration of everything in it rises sharply.

Two consequences follow. The peptide finds itself briefly at a far higher concentration than the label suggests, and association is concentration-dependent. And buffer components can crystallise at different rates, which shifts the pH of the remaining liquid away from where it was set, potentially toward the isoelectric point, where solubility is at its minimum.

High concentration plus altered pH at a surface is precisely the combination that drives aggregation, and the assembled state is generally more stable than the dispersed one, which is why the process does not simply reverse on thawing1. The mechanism is developed further in what a cloudy vial is telling you.

Cycles, not elapsed time

This reframes the question people usually ask. The concern is normally "how long can I keep it frozen", but the more important variable is how many times it crosses the transition.

Two stocks, same age, different histories

Why the number of cycles is the variable that matters

One vial, used six times

  • Six freeze, thaw cycles
  • Six passes through the concentrating interface
  • Each withdrawal also exposes the solution to room temperature and air

Six aliquots, used once each

  • One freeze, thaw cycle per portion
  • The rest of the material stays untouched until needed
  • Cost: a few minutes and six tubes

Both stocks in that comparison are the same age and have spent the same total time in the freezer. One has passed through the concentrating interface six times and the other once.

There is a secondary cost too. Each withdrawal warms the vial, exposes the solution to air, and often involves some agitation, and interfacial stress is an independent contributor to aggregation in protein preparations2.

Doing it properly takes five minutes

Aliquot at the moment you reconstitute, not later. Once a stock has been frozen and thawed, splitting it afterwards no longer avoids the cycle it already had.

Portion into the amount a single experiment consumes, with a little margin, a volume you will use entirely, so nothing is refrozen. Label each tube with the concentration, the solvent and the date, for the reason set out in the arithmetic behind the vial: a portion whose provenance you cannot reconstruct is a reagent with an unknown concentration.

Then thaw gently and without agitation, and use what you thawed.

The upstream decision

There is a step before all of this that removes the problem rather than managing it: reconstitute less.

The instinct is to dissolve the whole vial because that is what the vial contains. But nothing requires it. A smaller volume of stock, prepared for the work actually in front of you, leaves the rest of the material in the dry form, which, as covered in does it matter that the parcel was warm, is the state in which peptides are genuinely stable for long periods.

Powder in the freezer keeps. Solution in the freezer survives. The difference between those two verbs is the reason to leave as much of the vial as possible in the first category.

References

  1. 1. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry 2006 ; 75:333-366 doi:10.1146/annurev.biochem.75.101304.123901 ↩
  2. 2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010 ; 27(4):544-575 doi:10.1007/s11095-009-0045-6 ↩

This article summarises published research for educational purposes. It is not medical advice and does not describe permitted uses of any product. Compounds discussed are supplied strictly for in-vitro laboratory research and are not for human or animal consumption.

Continue reading

All The Lab →